NOVNz Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for NOVNz from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 95.56 |
| 52 Week High | CHF 102.72 |
| 52 Week Low | CHF 83.65 |
| Beta | 0.51 |
| 1 Month Change | 7.84% |
| 3 Month Change | 0.094% |
| 1 Year Change | 6.17% |
| 3 Year Change | 19.73% |
| 5 Year Change | n/a |
| Change since IPO | 92.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVNz | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 5.9% | 2.9% | 2.0% |
| 1Y | 6.2% | 3.5% | 10.8% |
Return vs Industry: NOVNz exceeded the UK Pharmaceuticals industry which returned 3.1% over the past year.
Return vs Market: NOVNz underperformed the UK Market which returned 10.4% over the past year.
Price Volatility
| NOVNz volatility | |
|---|---|
| NOVNz Average Weekly Movement | 2.2% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: NOVNz has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: NOVNz's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Novartis AG Fundamentals Summary
| NOVNz fundamental statistics | |
|---|---|
| Market cap | CHF 191.09b |
| Earnings (TTM) | CHF 10.87b |
| Revenue (TTM) | CHF 47.10b |
17.6x
P/E Ratio4.1x
P/S RatioIs NOVNz overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVNz income statement (TTM) | |
|---|---|
| Revenue | US$51.72b |
| Cost of Revenue | US$12.83b |
| Gross Profit | US$38.90b |
| Other Expenses | US$26.95b |
| Earnings | US$11.94b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | 5.97 |
| Gross Margin | 75.20% |
| Net Profit Margin | 23.09% |
| Debt/Equity Ratio | 67.1% |
How did NOVNz perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield68%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 01:02 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novartis AG is covered by 66 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |